Skip to content
  • Sunday, 26 July 2026
  • 2:57 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Everest Medicines Acquires Hasten Biopharmaceuticals for $250 Million to Bolster Asia Pacific Chronic Disease Portfolio and Commercial Reach
Pharmaceutical R&D

Everest Medicines Acquires Hasten Biopharmaceuticals for $250 Million to Bolster Asia Pacific Chronic Disease Portfolio and Commercial Reach

Teuku Ryan Apr 9, 2026 0

Everest Medicines, a leading biopharmaceutical company focused on developing and commercializing innovative medicines for chronic diseases, has announced a significant…

Read More
Pharmaceutical R&D

HNSCC market is expected to reach to $4.5bn across 8MM by 2034 – Pharmaceutical Technology

Teuku Ryan Apr 2, 2026 0

The global market for head and neck squamous cell carcinoma (HNSCC) therapeutics is poised for significant expansion, with projections indicating…

Read More
Pfizer and Astellas Secure FDA Priority Review for Perioperative Padcev and Keytruda Combination in Muscle-Invasive Bladder CancerTWiV 1293: The enemy of your parasite is your friendFrom Single Cell to Complex Consciousness Researchers Unveil How Lineage Based Organization Drives Brain DevelopmentUnlocking Superior Fruit Quality: "Housekeeping" Gene Discovery Promises Enhanced Nutrition and Flavor Without Sacrificing Plant Growth
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ